Karam Mounzer, MD
Infectious Diseases
Sees patients age 18 and up
Penn Infectious Diseases Penn Presbyterian
Penn Medicine Provider

About me

  • Chief Scientific Officer, Philadelphia FIGHT
  • Clinical Professor of Medicine (Infectious Diseases)

Education and training

  • Medical School: Saint Joseph's University Medical School
  • Residency: University of Medicine and Dentistry of New Jersey
  • Fellowship: University of Medicine and Dentistry of New Jersey

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Mounzer is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Maguire C, Rueve K, Farmer E, Huesgen E, Karaj A, Binkley A, Mounzer K, Brizzi M, Chary P, Sung P, Graziani A, Hiserodt E, Baron J, Koenig H, Short WR Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine. , Clin Infect Dis, 81(1): 2025,67-74


McMyn NF, Varriale J, Wu HWS, Hariharan V, Moskovljevic M, Tan TS, Lai J, Singhal A, Lynn K, Mounzer K, Tebas P, Montaner LJ, Hoh R, Yu XG, Lichterfeld M, Simonetti FR, Kovacs C, Deeks SG, Siliciano JM, Siliciano RF Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies. , J Clin Invest, 135(19): 2025,e194081


Mounzer K, Osterman MD, Brunet L, Hsu RK, Pierone G Jr, Fusco JS, Prata Menezes N, Gruber J, Lim T, Dunbar M, Fusco GP Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide. , AIDS Res Ther, 22(1): 2025,77


Pozniak A, Orkin C, Yazdanpanah Y, Baumgarten A, Mounzer K, D'Antoni ML, Huang H, Liu H, Andreatta K, VanderVeen LA, Callebaut C, Hindman JT, Arribas JR Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV. , Infect Dis Ther, 14(6): 2025,1201-1217


Mounzer K, Brunet L, Sension M, Hsu RK, Osterman MD, Fusco JS, Whiteside YO, Fusco GP Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study. , AIDS Res Ther, 22(1): 2025,64


Mohammed Zogheib, John Koethe, Jordan E. Lake, Karam Mounzer, Christian Caldji, Brandon Cash, Colleen McGary BMI Is a Poor Surrogate for Excess Visceral Adiposity and Cardiovascular Risk in Persons With HIV , CROI 2025, 5(1): 2025,239


Richard K, Yuan Z, Tang H-Y, Goldman AR, Kuthu R, Raphane B, Register ET, Sharma P, Ross BN, Morris J, Williams DE, Cheney C, Wu G, Mounzer K, Laird GM, Zuck P, Andersen RJ, Simonambango S, Andrae-Marobela K, Tietjen I, Montaner LJ Ex vivo and in vivo HIV-1 latency reversal by "Mukungulu," a protein kinase C-activating African medicinal plant extract. , mBio., 16(5): 2025,e0381624


Karam Mounzer, Laurence Brunet, Ricky K. Hsu, Philip C. Lackey, Michael Sension, Michael B. Wohlfeiler, Joshua Gruber, Megan S. Dunbar, Seojin Park, Jennifer S. Fusco, Gregory P. Fusco First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort , CROI, 3(1): 2025,123


Natalie F. McMyn, Joseph Varriale, Hanna Wu, Vivek Hariharan, Jun Lai, Anushka Singhal, Kenneth Lynn, Karam Mounzer, Pablo Tebas, Luis J. Montaner, Colin M. Kovacs, Rebecca Hoh, Steven G. Deeks, Janet M. Siliciano, Robert F. Siliciano Resistance of Inducible, Infectious HIV-1 to Autologous Neutralizing IgG After Long-Term ART , CROI: 2025


Malcolm Hedgcock, pedro.cahn, Mounzer, Karam, Peter Sklar, Mauricio Montezuma, Nicolas Margot, Xu Zhang, Chloe Orkin Demographic and clinical characteristics of Phase 3 participants in ARTISTRY-1, an open-label study comparing a bictegravir/lenacapavir (BIC/LEN) single tablet regimen (STR) with complex antiretroviral therapy (ART) regimens , EACS, 1(1): 2025,120